Luis Adrián De Jesús-González, Rosa María Del Ángel, Selvin Noé Palacios-Rápalo, Carlos Daniel Cordero-Rivera, Adrián Rodríguez-Carlos, Juan Valentin Trujillo-Paez, Carlos Noe Farfan-Morales, Juan Fidel Osuna-Ramos, José Manuel Reyes-Ruiz, Bruno Rivas-Santiago, Moisés León-Juárez, Ana Cristina García-Herrera, Adriana Clara Ramos-Cortes, Erika Alejandra López-Gándara, Estefanía Martínez-Rodríguez
Metformin (MET) and atorvastatin (ATO) are promising treatments for COVID-19. This review explores the potential of MET and ATO, commonly prescribed for diabetes and dyslipidemia, respectively, as versatile medicines against SARS-CoV-2. Due to their immunomodulatory and antiviral capabilities, as well as their cost-effectiveness and ubiquitous availability, they are highly suitable options for treating the virus. MET's effect extends beyond managing blood sugar, impacting pathways that can potentially decrease the severity and fatality rates linked with COVID-19...
February 13, 2024: Microorganisms